Your browser doesn't support javascript.
loading
A phase Ib feasibility trial of response adapted neoadjuvant therapy in gastric cancer (RANT-GC).
Dayyani, Farshid; Smith, Brian R; Nguyen, Ninh T; Daly, Shaun; Hinojosa, Marcelo W; Seyedin, Steven N; Kuo, Jeffrey; Samarasena, Jason B; Lee, John G; Taylor, Thomas H; Cho, May T; Senthil, Maheswari.
Afiliación
  • Dayyani F; Department of Medicine, University of California Irvine, Orange, CA 92868, USA.
  • Smith BR; Department of Surgery, University of California Irvine, Orange, CA 92868, USA.
  • Nguyen NT; Department of Surgery, University of California Irvine, Orange, CA 92868, USA.
  • Daly S; Department of Surgery, University of California Irvine, Orange, CA 92868, USA.
  • Hinojosa MW; Department of Surgery, University of California Irvine, Orange, CA 92868, USA.
  • Seyedin SN; Department of Radiation Oncology, University of California Irvine, Orange, CA 92868, USA.
  • Kuo J; Department of Radiation Oncology, University of California Irvine, Orange, CA 92868, USA.
  • Samarasena JB; Department of Medicine, University of California Irvine, Orange, CA 92868, USA.
  • Lee JG; Department of Medicine, University of California Irvine, Orange, CA 92868, USA.
  • Taylor TH; Department of Epidemiology, University of California Irvine, Irvine, CA 92617, USA.
  • Cho MT; Department of Medicine, University of California Irvine, Orange, CA 92868, USA.
  • Senthil M; Department of Surgery, University of California Irvine, Orange, CA 92868, USA.
Future Oncol ; 18(21): 2615-2622, 2022 Jul.
Article en En | MEDLINE | ID: mdl-35603628
ABSTRACT
Current guidelines recommend neoadjuvant (NAC) and/or adjuvant chemotherapy for locally advanced gastric cancers (LAGCs). However, the choice and duration of NAC regimen is standardized, rather than personalized to biologic response, despite the availability of several different classes of agents for the treatment of gastric cancer (GC). The current trial will use a tumor-informed ctDNA assay (Signatera™) and monitor response to NAC. Based on ctDNA kinetics, the treatment regimen is modified. This is a prospective single center, single-arm, open-label study in clinical stage IB-III GC. ctDNA is measured at baseline and repeated every 8 weeks. Imaging is performed at the same intervals. The primary end point is the feasibility of this approach, defined as percentage of patients completing gastrectomy.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Terapia Neoadyuvante Tipo de estudio: Diagnostic_studies / Guideline / Observational_studies Límite: Humans Idioma: En Revista: Future Oncol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Terapia Neoadyuvante Tipo de estudio: Diagnostic_studies / Guideline / Observational_studies Límite: Humans Idioma: En Revista: Future Oncol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos